STOCK TITAN
  1. Home
  2. IMMU

Immunomedics (IMMU) Stock Price, News & Analysis

IMMU NASDAQ

Company Description

Immunomedics (NASDAQ: IMMU) is classified in the biotechnology industry within the Health Technology sector.

This page collects what Stock Titan holds for IMMU, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
231.2M
Shares outstanding

Latest News

View All
+0.12%

Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

clinical trial fda approval
-0.14%

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

clinical trial
-0.14%

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

clinical trial
+0.22%

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

clinical trial
+4.27%

Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020

-2.47%

Immunomedics to Participate in Upcoming Healthcare Conferences

conferences

Immunomedics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include clinical trial, fda approval, conferences, earnings. View all IMMU news →

SEC Filings

View All

No SEC filings available for IMMU.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

IMMU Company Profile & Sector Positioning

Immunomedics (IMMU) operates in the Biotechnology industry within the broader Health Technology sector and is listed on the NASDAQ.